JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Fermé

SecteurSoins de santé

3.68 0.27

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.65

Max

3.8

Chiffres clés

By Trading Economics

Revenu

-15M

-40M

Ventes

8.2M

50M

Marge bénéficiaire

-80.43

Employés

435

EBITDA

-19M

-42M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+8.7% upside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

206M

1.3B

Ouverture précédente

3.41

Clôture précédente

3.68

Sentiment de l'Actualité

By Acuity

50%

50%

179 / 348 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 avr. 2026, 00:00 UTC

Principaux Événements d'Actualité

Australian Flash PMI Bounce in April Conceals Deeper Worries

22 avr. 2026, 23:33 UTC

Résultats

SK Hynix Posts Record Quarterly Results Amid AI Boom

22 avr. 2026, 22:40 UTC

Résultats

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22 avr. 2026, 22:10 UTC

Acquisitions, Fusions, Rachats

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22 avr. 2026, 21:11 UTC

Résultats

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22 avr. 2026, 21:01 UTC

Résultats

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22 avr. 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

22 avr. 2026, 23:46 UTC

Market Talk

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22 avr. 2026, 23:34 UTC

Market Talk
Principaux Événements d'Actualité

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22 avr. 2026, 23:16 UTC

Résultats

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22 avr. 2026, 23:15 UTC

Résultats

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22 avr. 2026, 22:54 UTC

Résultats

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22 avr. 2026, 22:54 UTC

Résultats

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22 avr. 2026, 22:52 UTC

Résultats

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22 avr. 2026, 22:51 UTC

Résultats

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22 avr. 2026, 22:31 UTC

Résultats

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22 avr. 2026, 22:31 UTC

Résultats

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22 avr. 2026, 22:30 UTC

Résultats

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22 avr. 2026, 22:30 UTC

Résultats

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22 avr. 2026, 22:29 UTC

Résultats

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22 avr. 2026, 22:28 UTC

Résultats

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22 avr. 2026, 22:28 UTC

Résultats

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22 avr. 2026, 22:27 UTC

Résultats

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22 avr. 2026, 22:06 UTC

Market Talk
Résultats

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22 avr. 2026, 21:55 UTC

Acquisitions, Fusions, Rachats

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22 avr. 2026, 21:47 UTC

Résultats

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 avr. 2026, 21:37 UTC

Résultats

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22 avr. 2026, 21:34 UTC

Résultats

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22 avr. 2026, 21:29 UTC

Résultats

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 avr. 2026, 21:20 UTC

Market Talk
Résultats

Tesla Expands Manufacturing to Chips -- Market Talk

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

8.7% hausse

Prévisions sur 12 Mois

Moyen 4 USD  8.7%

Haut 5 USD

Bas 3 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

6 ratings

3

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

2.02 / 2.115Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Sentiment

By Acuity

179 / 348Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat